[Are anxiety disorders associated to a particular addiction to smoking? Stress, anxiety and nicotine addiction].

This paper describes the relationship between several types of anxiety disorders and tobacco use. Possible explanations of those relationships are presented. Nicotine probably modulates the function of pathways involved in stress response and anxiety in the normal brain, which results in alterations of anxiety levels.

[How hypervigilance and hyperreactivity clinically described in anxiety expressed physiologically?].

Anxious people often show a particular attentional focus towards potentially threatening stimuli. Like any other emotion, anxiety goes along with physiological reactions, which may be more or less noticeable, and may impair behavior and physical wellness. In view of the psychophysiological reactions related with anxiety and anxiety disorders, it seems important to examine potential correlations between psychophysiological activity and the phenomena of hypervigilance.

[Pharmacotherapy of generalized anxiety disorder: state of the art].

A large percentage of patients in primary care suffer from Generalized Anxiety Disorder (GAD). A task force of the Swiss GAD Society has reviewed the scientific literature and has developed treatment recommendations. Basic treatment, adjunctive treatment and therapy of specific problems like insomnia and comorbidities are differentiated.

Bupropion-induced somnambulism.

Whereas there are some case reports of bupropion-induced vivid dreaming and nightmares, until now it has not been associated with somnambulism. A case is reported of a patient treated with bupropion as a smoking cessation medication, who developed somnambulism during nicotine withdrawal. Furthermore, the sleepwalking episodes were associated with eating behaviour.

Depersonalization-derealization syndrome induced by reboxetine.

A high variety of factors have been implicated in the emergence of depersonalisation and derealisation episodes, including different drugs. A case abruptly induced by two applications of reboxetine, a selective and specific norepinephrine reuptake inhibitor, is reported occurring in a 50-year-old woman treated for a major depressive episode. The episode rapidly remitted after discontinuation of reboxetine.